This study aimed to assess whether using GLP-1 RAs before MBS affects weight loss and improvements in obesity-related conditions over three years, in patients who switched to surgery due to an suboptimal response to GLP-1 therapy. The gene discussed is GCG; the disease is obesity disorder.